AR072571A1 - Composiciones monovalentes para union a cd28 y procedimientos de uso - Google Patents

Composiciones monovalentes para union a cd28 y procedimientos de uso

Info

Publication number
AR072571A1
AR072571A1 ARP090102734A ARP090102734A AR072571A1 AR 072571 A1 AR072571 A1 AR 072571A1 AR P090102734 A ARP090102734 A AR P090102734A AR P090102734 A ARP090102734 A AR P090102734A AR 072571 A1 AR072571 A1 AR 072571A1
Authority
AR
Argentina
Prior art keywords
domain
activity
domain antibody
union
procedures
Prior art date
Application number
ARP090102734A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41226147&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR072571(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co, Domantis Ltd filed Critical Bristol Myers Squibb Co
Publication of AR072571A1 publication Critical patent/AR072571A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)

Abstract

Anticuerpos de dominio que se unen de forma monovalente a CD28. Los anticuerpos de dominio que son monovalentes para la union a CD28 pueden inhibir la actividad de CD28. En un aspecto, un anticuerpo de dominio está constituido por o comprende un dominio variable de inmunoglobulina unico que se une específicamente y antagoniza la actividad de CD28 y, en un aspecto, sin agonizar sustancialmente la actividad de CD28. En otro aspecto, el anticuerpo de dominio es un anticuerpo de dominio humano. La descripcion incluye adicionalmente procedimientos para antagonizar las interacciones de CD80 y/o CD86 con CD28 en un individuo y procedimientos para tratar enfermedades o trastornos que implican interacciones de CD80 y/o CD86 con CD28, implicando los procedimientos la administracion de un anticuerpo de dominio al individuo.
ARP090102734A 2008-07-18 2009-07-17 Composiciones monovalentes para union a cd28 y procedimientos de uso AR072571A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8207808P 2008-07-18 2008-07-18
US16212109P 2009-03-20 2009-03-20

Publications (1)

Publication Number Publication Date
AR072571A1 true AR072571A1 (es) 2010-09-08

Family

ID=41226147

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102734A AR072571A1 (es) 2008-07-18 2009-07-17 Composiciones monovalentes para union a cd28 y procedimientos de uso

Country Status (30)

Country Link
US (6) US8168759B2 (es)
EP (2) EP2321352B1 (es)
JP (3) JP5675608B2 (es)
KR (2) KR101660057B1 (es)
CN (2) CN105936648B (es)
AR (1) AR072571A1 (es)
AU (1) AU2009270726B2 (es)
CA (1) CA2731220C (es)
CL (2) CL2011000117A1 (es)
CO (1) CO6341641A2 (es)
CY (1) CY1121796T1 (es)
DK (2) DK2321352T3 (es)
EA (1) EA024585B1 (es)
ES (2) ES2562629T3 (es)
HK (1) HK1155178A1 (es)
HR (2) HRP20160329T1 (es)
HU (2) HUE029982T2 (es)
IL (2) IL210413A (es)
LT (1) LT2700651T (es)
ME (1) ME02396B (es)
MX (1) MX2011000501A (es)
NZ (1) NZ590343A (es)
PE (2) PE20110385A1 (es)
PL (2) PL2321352T3 (es)
PT (2) PT2321352E (es)
RS (2) RS54675B1 (es)
SI (2) SI2700651T1 (es)
SM (1) SMT201600090B (es)
TW (2) TWI450725B (es)
WO (1) WO2010009391A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2479191A3 (en) 2005-05-18 2013-03-13 Ablynx N.V. Improved nanobodiesTM against tumor necrosis factor-alpha
US20110097339A1 (en) * 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
AU2009270726B2 (en) 2008-07-18 2015-07-09 Bristol-Myers Squibb Company Compositions monovalent for CD28 binding and methods of use
RU2540010C2 (ru) * 2009-02-25 2015-01-27 Некстера АС НЕЗАВИСИМЫЙ ОТ СИГНАЛЬНОЙ ПОСЛЕДОВАТЕЛЬНОСТИ ФАГОВЫЙ ДИСПЛЕЙ НА БЕЛКЕ pIX
FR2951176A1 (fr) * 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
EP2536764B1 (en) 2010-02-18 2018-07-04 OSE Immunotherapeutics Anti-cd28 humanized antibodies
EP2361935A1 (en) * 2010-02-18 2011-08-31 TcL Pharma Anti-CD28 humanized antibodies
WO2011156328A1 (en) * 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP5768022B2 (ja) * 2012-03-19 2015-08-26 株式会社東芝 メモリコントローラ、記憶装置、誤り訂正装置および誤り訂正方法
WO2014120916A1 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
EP3088411A4 (en) * 2013-12-27 2018-12-19 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
KR20160124912A (ko) * 2014-03-19 2016-10-28 브리스톨-마이어스 스큅 컴퍼니 Cd40l에 대해 지시된 도메인 항체를 사용하여 이식 거부를 치료하는 방법
TW201625688A (zh) 2014-09-12 2016-07-16 建南德克公司 經半胱胺酸改造之抗體及接合物
WO2016054218A1 (en) 2014-09-30 2016-04-07 Bristol-Myers Squibb Company Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28
WO2017160975A1 (en) 2016-03-16 2017-09-21 Bristol-Myers Squibb Company Methods of diagnosing and treating lupus
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
EP3619235A1 (en) 2017-04-11 2020-03-11 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2020028764A1 (en) 2018-08-03 2020-02-06 Bristol-Myers Squibb Company Methods for detecting anti-drug antibodies
AU2019383976A1 (en) 2018-11-19 2021-06-10 Biora Therapeutics, Inc. Methods and devices for treating a disease with biotherapeutics
CN113710704A (zh) * 2019-03-14 2021-11-26 比昂生物制剂公司 小脱落阻断剂
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
KR20220108137A (ko) * 2019-12-02 2022-08-02 비온드 바이오로직스 엘티디 Mmp 억제의 용도
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
AU2021213177A1 (en) * 2020-01-29 2022-08-18 Inhibrx Biosciences, Inc. CD28 single domain antibodies and multivalent and multispecific constructs thereof
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
JP2023536630A (ja) * 2020-08-04 2023-08-28 エグゼリクシス， インコーポレイテッド Ｐｄ－ｌ１結合性作用剤およびその使用
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
AU2022341016A1 (en) * 2021-09-06 2024-04-18 Biond Biologics Ltd. Cd28 shedding blocking agents
TW202400659A (zh) * 2022-05-04 2024-01-01 美商詹努克斯治療有限公司 經腫瘤活化之靶向ｃｄ２８及ｐｄ－ｌ１之多特異性抗體及其使用方法
WO2023215498A2 (en) * 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024077118A2 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839295A (en) 1984-06-08 1989-06-13 Pierce Chemical Company Measurement of protein using bicinchoninic acid
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
ES2322324T3 (es) 1992-08-21 2009-06-19 Vrije Universiteit Brussel Inmumoglobulinas desprovistas de cadenas ligeras.
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
ES2159726T3 (es) 1995-03-10 2001-10-16 Roche Diagnostics Gmbh Formas de administracion farmaceuticas que contienen polipeptidos, en forma de microparticulas, y procedimiento para su fabricacion.
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
CA2292415A1 (en) 1997-06-20 1998-12-30 Innogenetics N.V. B7-binding molecules for treating immune diseases
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
DE69921636T2 (de) 1998-04-20 2005-11-03 Genzyme Corp., Cambridge Medikamentöse verabreichung von proteinen aus polymergemischen
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
AU4770300A (en) 1999-05-14 2000-12-05 Medical Research Council Protein scaffold and its use to multimerise monomeric polypeptides
US20020006403A1 (en) * 1999-12-14 2002-01-17 Xue-Zhong Yu CD28-specific antibody compositions for use in methods of immunosuppression
DE60142794D1 (de) * 2000-12-26 2010-09-23 Inst Nat Sante Rech Med Antikörper gegen cd28
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
WO2002066059A2 (en) 2001-02-16 2002-08-29 Genetics Institute, Llc Agents that specifically block cd28-mediated signaling and uses therefor
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
WO2004058821A2 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
DK1419179T3 (da) 2001-08-10 2010-06-21 Univ Aberdeen Antigenbindingsdomæner fra fisk
WO2003031611A2 (en) 2001-10-05 2003-04-17 Cangene Corporation Phagemid display system
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
DE10156482A1 (de) * 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
JP2006512895A (ja) 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
WO2004041862A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US7635472B2 (en) 2003-05-31 2009-12-22 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
CN101061140B (zh) * 2004-09-17 2015-07-01 多曼蒂斯有限公司 单价结合cd40l的组合物和应用方法
GB0614093D0 (en) 2006-07-14 2006-08-23 Bae Systems Plc Deployable antenna system
CA2672595A1 (en) * 2006-12-15 2008-06-19 Guy Hermans Amino acid sequences that modulate the interaction between cells of the immune system
AU2009270726B2 (en) 2008-07-18 2015-07-09 Bristol-Myers Squibb Company Compositions monovalent for CD28 binding and methods of use
AU2009284113B2 (en) 2008-08-21 2015-05-14 Octapharma Ag Recombinantly produced human factor VIII and IX
KR20160124912A (ko) * 2014-03-19 2016-10-28 브리스톨-마이어스 스큅 컴퍼니 Cd40l에 대해 지시된 도메인 항체를 사용하여 이식 거부를 치료하는 방법
WO2016054218A1 (en) * 2014-09-30 2016-04-07 Bristol-Myers Squibb Company Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28

Also Published As

Publication number Publication date
AU2009270726B2 (en) 2015-07-09
RS54675B1 (en) 2016-08-31
HUE029982T2 (en) 2017-04-28
PE20140852A1 (es) 2014-07-14
CL2012002428A1 (es) 2013-01-11
RS58904B1 (sr) 2019-08-30
JP6058833B2 (ja) 2017-01-11
US9908937B2 (en) 2018-03-06
CN105936648B (zh) 2020-06-16
CN105936648A (zh) 2016-09-14
HRP20160329T1 (hr) 2016-04-22
IL251320B (en) 2019-01-31
CA2731220C (en) 2017-10-10
SI2700651T1 (sl) 2019-08-30
CA2731220A1 (en) 2010-01-21
US9085629B2 (en) 2015-07-21
IL210413A (en) 2017-04-30
CN102159590A (zh) 2011-08-17
US20150299321A1 (en) 2015-10-22
LT2700651T (lt) 2019-06-25
DK2700651T3 (da) 2019-07-22
SI2321352T1 (sl) 2016-04-29
IL210413A0 (en) 2011-03-31
JP2011528551A (ja) 2011-11-24
US20180142023A1 (en) 2018-05-24
TWI450725B (zh) 2014-09-01
CO6341641A2 (es) 2011-11-21
AU2009270726A1 (en) 2010-01-21
PT2321352E (pt) 2016-03-18
EP2321352B1 (en) 2016-01-06
HUE045249T2 (hu) 2019-12-30
US20210047414A1 (en) 2021-02-18
JP5876134B2 (ja) 2016-03-02
PE20110385A1 (es) 2011-06-22
US10919965B2 (en) 2021-02-16
KR101660057B1 (ko) 2016-09-26
PL2700651T3 (pl) 2019-09-30
PT2700651T (pt) 2019-06-19
JP2016063830A (ja) 2016-04-28
JP5675608B2 (ja) 2015-02-25
NZ590343A (en) 2012-10-26
JP2015120695A (ja) 2015-07-02
KR101791372B1 (ko) 2017-10-27
DK2321352T3 (en) 2016-04-04
US12012452B2 (en) 2024-06-18
IL251320A0 (en) 2017-05-29
US20120201814A1 (en) 2012-08-09
EA024585B1 (ru) 2016-10-31
KR20110041527A (ko) 2011-04-21
PL2321352T3 (pl) 2016-06-30
EP2700651B1 (en) 2019-04-10
EA201100239A1 (ru) 2011-10-31
HRP20190966T1 (hr) 2019-07-26
US8168759B2 (en) 2012-05-01
ME02396B (me) 2016-08-31
MX2011000501A (es) 2011-05-23
SMT201600090B (it) 2016-04-29
EP2700651A1 (en) 2014-02-26
TW201336510A (zh) 2013-09-16
HK1155178A1 (zh) 2012-05-11
US20100028354A1 (en) 2010-02-04
ES2562629T3 (es) 2016-03-07
EP2321352A1 (en) 2011-05-18
US20130109846A1 (en) 2013-05-02
ES2730727T3 (es) 2019-11-12
TW201006494A (en) 2010-02-16
WO2010009391A1 (en) 2010-01-21
CY1121796T1 (el) 2020-07-31
US8454959B2 (en) 2013-06-04
CL2011000117A1 (es) 2011-06-17
KR20160113322A (ko) 2016-09-28

Similar Documents

Publication Publication Date Title
AR072571A1 (es) Composiciones monovalentes para union a cd28 y procedimientos de uso
AR073459A1 (es) Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso
BR112012023010A8 (pt) Anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37
CL2020000452A1 (es) Anticuerpos de b7-h4 y métodos para usarlos.
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
PE20181349A1 (es) Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
CO2017011486A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
AR077333A1 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina -2 humana
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
AR083044A1 (es) Anticuerpos anti-cd48 y usos de los mismos
BR112015014751A2 (pt) anticorpos anti-tau humanos
MX2014001799A (es) Anticuerpos sin fc qie comprenden dos fragmentos fab y metodos de uso.
CO2018003852A2 (es) Proteínas de unión a antigeno que activan el receptor de leptina
AR084315A1 (es) Anticuerpos anti-notch1
CY1118551T1 (el) Μεθοδοι θεραπειας αυτοανοσων νοσων με ανταγωνιστες του dll4
AR085600A1 (es) Agentes de union biespecifica
RS54795B1 (sr) Anti-her3 antitela i njihova korišćenja
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
PE20091520A1 (es) Anticuerpos bivalentes biespecificos
AU2014247175A8 (en) Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use
PE20141158A1 (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapeutico
PE20141659A1 (es) Dominios variables singulares anti-vgf fusionados con dominios de fc
PE20081478A1 (es) Anticuerpos cd44
BR112013031485A8 (pt) Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais
BR112022009723A2 (pt) Anticorpos específicos para cd47, pd-l1, e usos dos mesmos

Legal Events

Date Code Title Description
FG Grant, registration